top of page

An AI-Powered Discovery Engine
for the Development of
Advanced Immune Therapeutics

Home: Welcome

Flex-NK™ Bispecific Antibodies to Redirect
& Activate NK Cells At the Tumor Site

Screenshot 2023-10-17 at 16.22.11.png

Cytovia Therapeutics R&D Team Presents Poster at ASGCT 2023 on GPC3-Targeted TALEN® Gene-Edited CAR-iNK Cell

April 17th, 2023

Cytovia Therapeutics R&D Team Presents 2 Posters at AACR 2023 on GPC3-Targeted Bispecific Antibody & TALEN® Gene-Edited iNK Cells

April 17th, 2023

See All News & Events

Cytovia Therapeutics R&D Leadership Presents Updated Data at Innate Killer Summit in San Diego

March 31st, 2023

What's New at Cytovia

Cytovia Therapeutics: An NK Revolution Towards a Cancer Cure

05:50

Cytovia Therapeutics: An NK Revolution Towards a Cancer Cure

From Vision to Execution: Cytovia at a Strategic Inflection Point

03:36

From Vision to Execution: Cytovia at a Strategic Inflection Point

Introducing Our New R&D Center of Excellence (With CSO Dr. Wei Li)

03:10

Introducing Our New R&D Center of Excellence (With CSO Dr. Wei Li)

A Conversation with Board Director Michael Friedman, MD

05:30

A Conversation with Board Director Michael Friedman, MD

A Conversation With Scientific Advisor Michael Caligiuri, MD

08:41

A Conversation With Scientific Advisor Michael Caligiuri, MD

A Conversation with Scientific Advisor Justin Eyquem, PhD

06:16

A Conversation with Scientific Advisor Justin Eyquem, PhD

A Conversation with Board Directors Laurent Audoly, PhD & Leila Alland, MD

06:47

A Conversation with Board Directors Laurent Audoly, PhD & Leila Alland, MD

A Conversation With Chief Scientific Officer Wei Li, PhD

06:20

A Conversation With Chief Scientific Officer Wei Li, PhD

bottom of page